Literature DB >> 25902136

Presentation and outcome of a cluster of patients with endogenous endophthalmitis: a case series.

J Guber1, M U Saeed1.   

Abstract

BACKGROUND: The aim of this study was to investigate the clinical features and visual acuity outcomes associated with endogenous endophthalmitis.
MATERIAL AND METHODS: Seven eyes of 6 patients treated at Epsom and St Helier University Hospitals between 2010 and 2013 were reviewed for endogenous endophthalmitis.
RESULTS: Patients were followed for a mean of 7 months (range 1 to 13). Positive blood cultures were obtained in 5 patients (83%), including 1 patient with fungal isolates (17%), two patients with Gram-positive isolates and another two with Gram-negative isolates. Five patients (83%) were hospitalized at the time of diagnosis and 2 patients (33%) died within 6 months of diagnosis. Initial treatment included vitreous tap and injection of intravitreal antibiotics. Only in one eye (14%) were positive results from the biopsy obtained. Four eyes (57%) achieved a final visual acuity of >6/60. Patients with a Klebsiella endophthalmitis had worse visual outcome.
CONCLUSIONS: Endogenous endophthalmitis is generally associated with high mortality and poor visual acuity outcomes. Gram-negative species are associated with poorer visual acuity. Vitreous biopsy has a weak diagnostic relevance as is it often negative. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25902136     DOI: 10.1055/s-0034-1396328

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  Mortality risk associated with endophthalmitis in West Virginia.

Authors:  Jeffrey Desilets; Chang Sup Lee; Wei Fang; David M Hinkle
Journal:  Int Ophthalmol       Date:  2021-04-16       Impact factor: 2.029

2.  Endogenous Endophthalmitis: yield of the diagnostic evaluation.

Authors:  Kathleen A Regan; Nila S Radhakrishnan; Jon D Hammer; Benjamin D Wilson; Lara Beth Gadkowski; Siva S R Iyer
Journal:  BMC Ophthalmol       Date:  2020-04-07       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.